Compare PMTS & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMTS | BNTC |
|---|---|---|
| Founded | 2007 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 280.3M | 313.9M |
| IPO Year | 2015 | 2020 |
| Metric | PMTS | BNTC |
|---|---|---|
| Price | $25.42 | $8.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $32.50 | $24.33 |
| AVG Volume (30 Days) | ★ 238.6K | 176.7K |
| Earning Date | 11-03-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.67 |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $312,189,000.00 | N/A |
| Revenue This Year | $11.19 | N/A |
| Revenue Next Year | $8.16 | N/A |
| P/E Ratio | $73.53 | ★ N/A |
| Revenue Growth | ★ 12.27 | N/A |
| 52 Week Low | $10.81 | $8.52 |
| 52 Week High | $31.25 | $16.76 |
| Indicator | PMTS | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 51.30 | 29.49 |
| Support Level | $18.46 | N/A |
| Resistance Level | $29.57 | $13.49 |
| Average True Range (ATR) | 0.60 | 0.78 |
| MACD | 0.11 | -0.07 |
| Stochastic Oscillator | 89.47 | 10.90 |
CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit segment, which principally produce secure debit and credit cards and provide card services for U.S. card-issuing financial institutions, including personalization, instant issuance and other payment solutions such as digital push provisioning for mobile wallets; Prepaid Debit, which provides secure packaging solutions, Prepaid Debit Cards, and other integrated prepaid card services to prepaid program managers in the U.S.; and other: principally corporate expenses. The firm generates key revenue from Debit and Credit segment.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.